real-time news and commentary for investors
Friday, Sep 20
Leerink talks Prosensa after ghastly sell-off
- For what it's worth (which might not be much after Friday's 70% rout), Leerink sees some upside for Prosensa (RNA) from current levels.
- Analyst Joseph Schwartz says the shares could go to $11 based on "the promising efficacy signal seen in patients below 7-years old and the fact that pooling DEMAND III data with strong DEMAND II and DEMAND V results could demonstrate that a clinically significant drisapersen treatment benefit is likely."
- Adding insult to injury today for RNA shareholders is Sarepta (SRPT), which closed 18% higher after falling 10% premarket following the drisapersen news.
- See previous coverage for more.